Literature DB >> 2822841

Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody.

V Sullivan1, G L Smith.   

Abstract

A recombinant vaccinia virus expressing herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) has been constructed. Cells infected with this recombinant virus (gG-VAC) synthesized glycosylated proteins of 48K, 57K and 61K mol. wt. that were recognized by anti-HSV-1 sera. Rabbits and mice vaccinated with the live recombinant virus produced antibodies that recognized 48K, 57K and 61K mol. wt. proteins in HSV-1-infected cells. The gG polypeptides were present on cytoplasmic and nuclear membranes during infection with both HSV-1 and recombinant vaccinia virus gG-VAC. The 57K and 61K mol. wt. gG polypeptides were present in purified HSV-1 virions and were targets for antibody-mediated complement-dependent virus neutralization.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2822841     DOI： 10.1099/0022-1317-68-10-2587

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  11 in total

1.  Application of a transformed cell line constitutively expressing HSV-1 polypeptides for the detection of HSV antibodies in human sera by an enzyme immunoassay.

Authors:  A Sivropoulou; A Vasilaki; M Arsenakis
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Vaccinia virus encodes a polypeptide with DNA ligase activity.

Authors:  S M Kerr; G L Smith
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

3.  Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.

Authors:  P X Guo; S Goebel; M E Perkus; J Taylor; E Norton; G Allen; B Languet; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 4.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

5.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.

Authors:  P X Guo; S Goebel; S Davis; M E Perkus; B Languet; P Desmettre; G Allen; E Paoletti
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus.

Authors:  C D Bayliss; R W Peters; J K Cook; R L Reece; K Howes; M M Binns; M E Boursnell
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Herpes simplex virus glycoprotein K is known to influence fusion of infected cells, yet is not on the cell surface.

Authors:  L Hutchinson; C Roop-Beauchamp; D C Johnson
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

Authors:  M P Cranage; G L Smith; S E Bell; H Hart; C Brown; A T Bankier; P Tomlinson; B G Barrell; T C Minson
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  Expression of the Marek's disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV.

Authors:  M Niikura; Y Matsuura; D Endoh; M Onuma; T Mikami
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

Authors:  Xiaoxing Huang; Bin Lu; Wenbo Yu; Qing Fang; Li Liu; Ke Zhuang; Tingting Shen; Haibo Wang; Po Tian; Linqi Zhang; Zhiwei Chen
Journal:  PLoS One       Date:  2009-01-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.